Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | ITGB1 | P05556 | 7/20 | 0.33 |
| ▸ | ITGA4 | P13612 | 7/20 | 0.33 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7579993 | 0.90 | P2RX7 (0.32) | PTGESP2RX7 | |
| SCHEMBL4563392 | 0.87 | ITGB1 (0.34) | ITGB1ITGA4TAS2R14 | |
| SCHEMBL4562546 | 0.86 | CYP2C9 (0.43) | ITGB1ITGA4ALOX5KMT2AALDH1A1 | |
| SCHEMBL3852380 | 0.83 | PTGES (0.37) | PTGESP2RX7CNR2ITGB1ITGA4 | |
| SCHEMBL4564688 | 0.80 | BMP1 (0.30) | — | |
| SCHEMBL3851526 | 0.80 | PTGES (0.36) | PTGESP2RX7CNR2ITGB1ITGA4 | |
| SCHEMBL3858269 | 0.79 | PTGES (0.37) | PTGESP2RX7CNR2ITGB1ITGA4 | |
| SCHEMBL4563287 | 0.79 | RORC (0.32) | — | |
| SCHEMBL4563268 | 0.79 | P2RX7 (0.32) | PTGESP2RX7CNR2KMT2A | |
| SCHEMBL4563523 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1592387-A4 | COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS | ELAN PHARM INC (US) | 2009-05-06 | — | — | EP | disclosed |
| EP-1592387-A2 | COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS | Elan Pharmaceuticals, Inc. (US) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004066932-A2 | COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS | ELAN PHARMACEUTICALS INC. (US) | 2004-08-12 | — | — | WO | disclosed |